2013

Wagner M, Koslowski M, Paret C, Schmidt M, Türeci O, Sahin U: NCOA3 is a selective co-activator of estrogen receptor α-mediated transactivation of PLAC1 in MCF-7 breast cancer cells. BMC cancer 2013, 13:570.
DOI; PubMed

Kloke B, Rae R, Mahr A, Burkhardt UE, Kvistborg P, Britten CM: Toward the next waves of cancer immunotherapy: 11th Annual Meeting of the Association for Cancer Immunotherapy (CIMT), Mainz, Germany, May 14-16, 2013. Cancer immunology, immunotherapy: CII 2014, 63:749-755.
DOI; PubMed
Cabezas-Wallscheid N, Eichwald V, Graaf J de, Löwer M, Lehr H, Kreft A, Eshkind L, Hildebrandt A, Abassi Y, Heck R, Dehof AK, Ohngemach S, Sprengel R, Wörtge S, Schmitt S, Lotz J, Meyer C, Kindler T, Zhang D, Kaina B, Castle JC, Trumpp A, Sahin U, Bockamp E: Instruction of haematopoietic lineage choices, evolution of transcriptional landscapes and cancer stem cell hierarchies derived from an AML1-ETO mouse model. EMBO Mol Med 2013, 5:1804-1820.
DOI; PubMed

Britten CM, Singh-Jasuja H, Flamion B, Hoos A, Huber C, Kallen K, Khleif SN, Kreiter S, Nielsen M, Rammensee H, Sahin U, Hinz T, Kalinke U: The regulatory landscape for actively personalized cancer immunotherapies. Nature biotechnology 2013, 31:880-882.
DOI; PubMed

Diken M, Kreiter S, Vascotto F, Selmi A, Attig S, Diekmann J, Huber C, Türeci Ö, Sahin U: mTOR inhibition improves antitumor effects of vaccination with antigen-encoding RNA. Cancer immunology research 2013, 1:386-392.
DOI; PubMed

Wöll, S., Schlitter, A.M., Dhaene, K., Roller, M., Esposito, I., Sahin, U., Türeci, Ö. (2013) Claudin 18.2 is a target for IMAB362 antibody in pancreatic neoplasms. Int J Cancer. 2013 Jul 30.
DOI; PubMed

Britten CM, Walter S, Janetzki S: Immunological Monitoring to Rationally Guide AAV Gene Therapy. Frontiers in immunology 2013, 4:273.
DOI; PubMed

Cron A, Gouttefangeas C, Frelinger J, Lin L, Singh SK, Britten CM, Welters MJP, van der Burg, Sjoerd H., West M, Chan C, Altan-Bonnet G: Hierarchical Modeling for Rare Event Detection and Cell Subset Alignment across Flow Cytometry Samples. PLoS Comput Biol 2013, 9:e1003130.
DOI; PubMed

Janetzki S, Hoos A, Melief, Cornelis J M, Odunsi K, Romero P, Britten CM: Structured reporting of T cell assay results. Cancer immunity 2013, 13:13.
PubMed

Diken M, Attig S, Grunwitz C, Kranz L, Simon P, van de Roemer, Niels, Vascotto F, Kreiter S: CIMT 2013: advancing targeted therapies–report on the 11th Annual Meeting of the Association for Cancer Immunotherapy, May 14-16 2013, Mainz, Germany. Human vaccines & immunotherapeutics 2013, 9:2025-2032.
DOI; PubMed

Sahin U, Türeci O: Antigen identification using SEREX. Methods in molecular biology (Clifton, N.J.) 2013, 1061:59-77.
DOI; PubMed

McNeil LK, Price L, Britten CM, Jaimes M, Maecker H, Odunsi K, Matsuzaki J, Staats JS, Thorpe J, Yuan J, Janetzki S: A harmonized approach to intracellular cytokine staining gating: Results from an international multiconsortia proficiency panel conducted by the Cancer Immunotherapy Consortium (CIC/CRI). Cytometry 2013, 83A:728-738.
DOI; PubMed

Warminski M, Kowalska J, Buck J, Zuberek J, Lukaszewicz M, Nicola C, Kuhn AN, Sahin U, Darzynkiewicz E, Jemielity J: The synthesis of isopropylidene mRNA cap analogs modified with phosphorothioate moiety and their evaluation as promoters of mRNA translation. Bioorganic & medicinal chemistry letters 2013, 23:3753-3758.
DOI; PubMed

Neufert C, Becker C, Türeci Ö, Waldner MJ, Backert I, Floh K, Atreya I, Leppkes M, Jefremow A, Vieth M, Schneider-Stock R, Klinger P, Greten FR, Threadgill DW, Sahin U, Neurath MF: Tumor fibroblast-derived epiregulin promotes growth of colitis-associated neoplasms through ERK. The Journal of clinical investigation 2013, 123:1428-1443.
DOI
; PubMed

Scholtalbers J, Rößler J, Sorn P, Graaf J de, Boisguérin V, Castle J, Sahin U: Galaxy LIMS for next-generation sequencing. Bioinformatics (Oxford, England) 2013, 29:1233-1234.
DOI
; PubMed

Schröder JC, Läßig AK, Galetzka D, Peters A, Castle JC, Diederich S, Zechner U, Müller-Forell W, Keilmann A, Bartsch O: A boy with homozygous microdeletion of NEUROG1 presents with a congenital cranial dysinnervation disorder [Moebius syndrome variant]. Behavioral and brain functions: BBF 2013, 9:7.
DOI
; PubMed

Kloke B, Kutscher S, Rae R, Kvistborg P, Britten CM, Hadrup SR: Toward next-generation cancer immunotherapy: 10th annual meeting of the Association for Cancer Immunotherapy (CIMT), Mainz, Germany, May 23-25, 2012. Cancer immunology, immunotherapy: CII 2013, 62:975-981.
PubMed